Nilox midi

Nitroxoline

Method of action: Anti-Inflammatory

Treatment option: Prostatitis, Urethritis, Cystitis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nilox midi

Nilox midi is an anti-infective medicinal preparation primarily defined by its single active component, Nitroxoline, and its specific classification as a uro-antiseptic agent. This section establishes the fundamental identity, origin, and pharmacological category of the medicine.

Property	Description
Active ingredient	Nitroxoline
Form	Film-coated tablet (Oral solid dosage form)
Pharmacological class	Anti-infective agent, Synthetic chemotherapeutic agent
Common use	Combating infections, particularly in the urinary system
Origin	Synthetic compound (8-hydroxyquinoline derivative)

What is Nilox midi and its Active Component?

Nilox midi is a prescription anti-infective medicine whose effect is based on the single active ingredient, Nitroxoline (5-nitro-8-hydroxyquinoline). It is supplied in a solid, oral dosage form, typically presented as a film-coated tablet intended for ingestion.

The compound Nitroxoline is a synthetic compound, specifically a manufactured chemical derivative of 8-hydroxyquinoline, and is classified as a single-agent product. The molecule’s structure, which includes a nitro group, is associated with the drug's targeted effectiveness against susceptible pathogens.

Nilox midi: Classification as a Uro-antiseptic Chemotherapeutic Agent

Nilox midi is categorized as a synthetic chemotherapeutic agent belonging to the broader pharmacological class of anti-infective agents. It is specifically designated as a uro-antiseptic due to its unique pharmacological behavior of concentrating significantly within the urinary system after oral administration.

Nitroxoline exhibits broad-spectrum capability against both certain bacteria and fungi by inhibiting microbial nucleic acid synthesis. This characteristic reinforces the drug's utility in targeting a wide array of common microbial pathogens. Unlike some purely systemic antibiotics, the uro-antiseptic focus means its primary utility is concentrated on managing infectious processes within the structures of the urinary tract, serving a specific need within infection management.

General Purpose and Effect of the Medicine

The core general purpose of Nilox midi is to combat infections by interfering with and halting the proliferation of susceptible microbial pathogens. The active agent acts by disrupting the life-sustaining internal processes of these microorganisms, thereby assisting the body in resolving the overall microbial burden. This action aims to establish a local environment where pathogens cannot sustain growth, which is a key defining aspect of its utility as an anti-infective drug, particularly when addressing infections localized to the urinary system.

What side effects are possible with Nilox midi?

Possible Side Effects and Safety Information

Official regulatory documentation for Nitroxoline details the safety profile, classifying potential adverse reactions by frequency and body system involvement based on clinical use and surveillance. The safety information includes expected physiological changes and defined constraints for use.

Documented Adverse Reactions by Frequency

Reactions are classified using standard regulatory frequency tiers:

Common Reactions The most frequently reported effects are gastrointestinal complaints, including nausea, vomiting, and diarrhoea. These manifestations are generally observed to recede during the course of treatment.
Uncommon Reactions These include allergic skin reactions, such as reddening and itching, which are typically temporary or resolve spontaneously after stopping intake.
Rare and Very Rare Reactions Rare effects involve the blood and lymphatic system, presenting as allergic changes to the blood count, specifically a reduction of the number of blood platelets. Severe allergic reactions are also rare, linked to excipients like Soy oil and Ponceau 4R (E 124). Very rare reports include neurological side-effects (fatigue, headaches, vertigo, insecurity of gait) and a temporary yellow colouring of the sclera of the eye.

Administration-Agnostic Safety Characteristics

The active substance's excretion pathway results in an unobjectionable yellow coloration of the urine, which is an expected characteristic. Rarely, slight excretion via sweat may lead to a temporary yellow coloration of the skin, hair, and nails.

Population-Specific Safety Considerations

The official label states that the medicine should not be used during lactation. This is a defined safety constraint due to lack of data on passage into breast milk and concern for influence on the physiological intestinal flora, potentially causing diarrhoea or the settlement of yeast-like fungi in the breast-fed baby.

Overdose and Emergency Response

Overdose and When to Seek Help

The official information regarding an overdose of Nilox midi (Nitroxoline) is primarily focused on required emergency actions and population-specific risks, rather than a common list of acute symptoms. Regulatory documents state that no specific side-effects of excessively high doses have been formally documented or observed. However, the regulatory guidance strictly mandates that immediate medical help must be sought if a very high dose has been ingested. For instances of slight overdose, official information suggests that no specific measures are generally necessary.

The most critical regulatory concern involves specific populations. The official prescribing information identifies an increased risk of overdose toxicity in patients who have severe renal impairment, defined as a Glomerular Filtration Rate (GFR) less than 30 mL/min. Furthermore, a risk of cardiac conduction disorders is identified in patients who have pre-existing conduction abnormalities, such as bradycardia, following an overdose.

Because of these systemic risks in vulnerable groups, all cases of suspected very high overdose require consultation with a doctor to determine appropriate supportive and symptomatic management, as a specific antidote is not listed in regulatory labeling. This ensures any potential severe outcomes, particularly affecting the kidneys or heart in at-risk individuals, are addressed promptly by a healthcare professional.

Therapeutic Uses of Nilox midi

What Nilox midi Treats: Main Uses and Benefits

Nilox midi is a medication generally used in situations involving certain distressing symptoms across three primary symptom axes: pain, inflammation, and fever. It is applied across domains where additional symptomatic support is needed to address discomfort. This category of medication is recognized for its relevance in managing symptoms related to these three areas.

Symptom Management and Patient Comfort

This medication is relevant for managing symptom clusters that may become intense or disruptive, such as aches, muscle pain, headaches, swelling, redness, and elevated body temperature. It is commonly used across conditions presenting with acute episodes where symptoms create noticeable physiological strain.

Quick Fact: Relief for Pain and Fever

The medication is relevant when supportive symptom management is appropriate, and is commonly used across conditions presenting with acute episodes.

“This medication provides support that helps ease the overall symptom burden and assists with maintaining functional stability when symptoms are more noticeable.”

Nilox midi offers symptomatic relief that helps patients cope more steadily with difficult episodes, supporting general well-being during symptomatic phases.

Regulatory References

NIH MedlinePlus overview on NSAIDs

Eligibility and Restrictions for Use

Who Can and Cannot Use Nilox midi?

This section outlines the officially documented population eligibility rules for Nilox midi (Nitroxoline), based strictly on regulatory prescribing information. Eligibility is defined by absolute contraindications, organ function status, and life stage.

Populations and Conditions Prohibited from Use

Classification	Population/Condition
Absolute Contraindication	Known hypersensitivity to Nitroxoline or other 8-hydroxyquinoline derivatives.
Organ Impairment	Severe hepatic impairment or severe renal impairment (e.g., anuria).

Populations with Restricted or Conditional Use

Classification	Population/Condition
Reproductive Status	Use during pregnancy is restricted to situations considered medically necessary. Use during lactation is generally not recommended.
Age Limits	The film-coated tablet formulation is typically not intended for children under a specified minimum age (often 4 years). Older adults require special care during use.
Organ Monitoring	Patients with non-severe limited renal function require close monitoring due to the potential for delayed excretion of the drug.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Nilox midi (Nitroxoline) as described in regulatory prescribing information.

Documented Drug-Drug Interactions

Classification	Interacting Agents	Official Interaction Statement
Pharmacodynamic & Exposure-Altering	Coumarin-type Anticoagulants (e.g., Warfarin, Acenocoumarol)	Co-administration is formally documented to increase the therapeutic efficacy of the anticoagulant substance.

The official interaction profile is defined by this specific effect on Coumarin-type Anticoagulants. This outcome necessitates attention as it results in an altered effect profile for the co-administered drug. The interaction is classified as significant and typically requires professional assessment.

Other Interaction Categories

Regulatory documentation does not specify mandatory timing-based separation rules for administration with other products. Furthermore, Nilox midi does not have officially documented interactions with food, alcohol, herbal products, or supplements in the primary regulatory summaries. Similarly, there are no explicitly documented interactions mediated by specific CYP450 enzymes or drug transporters in the regulatory information.

Mechanism of Action

The action of Nilox midi is driven entirely by its active component, Nitroxoline, which exerts its effect through targeted interference with the fundamental processes that sustain microbial life.

Targeted Inhibition through Essential Metal Chelation

The primary mechanism involves chelation, where Nitroxoline strongly binds to and removes essential divalent metal cations (such as Zn^2+ and Mg^2+) from the microbial environment. These metals are critical cofactors for numerous life-sustaining enzymes in the pathogen. This action results in the deprivation of necessary metal ion cofactors for susceptible microbes, establishing the foundational step in the anti-infective cascade.

Disruption of Microbial Genetic Replication

The resulting metal ion deprivation leads directly to the inactivation of microbial metalloenzymes like Ribonucleotide Reductase (RNR). By inhibiting RNR, the drug blocks the synthesis of DNA precursors required for cell division and replication. This cascading effect produces the key physiological consequence of inhibiting pathogen proliferation, which reduces the overall microbial population density. The chelation capacity is dependent on the local pH level; this mechanistic interaction is reduced in less acidic environments.

Dosage and Administration Information

How to Use Nilox midi: Official Administration Guidelines

Nilox midi is an anti-infective agent strictly intended for oral administration, typically provided as a film-coated tablet or capsule with a standard strength of 250 mg of Nitroxoline. The usage is structured according to the therapeutic goal: treating an active infection or providing relapse prevention.

For the standard therapeutic adult dose, the regimen requires the 250 mg unit to be administered in a divided schedule of three times a day (TID), leading to a total intake of 750 mg daily. Clinical use frequently employs this dosage for a seven-day course, though the total duration must be completed as prescribed and not stopped early. For recurrence prophylaxis, the frequency is reduced to a single daily dose, often recommended for intake in the evening.

Specific administration conditions govern intake timing. The tablet must be taken with a glass of water and ideally one hour before meals to promote optimal absorption. If this timing causes gastrointestinal discomfort, the dose may be taken immediately after a meal. Procedurally, if a dose is forgotten, continuity is maintained by taking the next scheduled dose as planned, without compensating by doubling the missed amount. High-level prescribing rules also indicate that use must consider or preclude the presence of severe renal or hepatic function disorders.

Recent Clinical Evidence

Research evidence / Overview of studies for Nilox midi

Evidence for Uncomplicated UTI (uUTI)

The research base for Nilox midi's use in uncomplicated urinary tract infection (uUTI) primarily relies on meta-analyses that re-evaluated data from older controlled trials. These studies, conducted largely in adult females, examined both microbiological outcomes (bacteria elimination) and the assessment of symptom changes during short treatment periods (5 to 10 days). Findings reported patterns of microbiological clearance. A key limitation is the reliance on historical data, as modern, large-scale Randomized Controlled Trials (RCTs) using current standards are scarce.

Prophylaxis and Extended Observation

Research explored the use of Nilox midi for prophylaxis (prevention of recurrence) in patients with a history of recurrent UTIs. This evidence comes from older clinical trials that monitored changes in the frequency of relapse over intermediate time periods. The certainty remains low for this indication, as follow-up durations were often limited and the information for long-term outcomes remains insufficient across the board.

Research on Resistant Organisms and Patient Groups

Studies have conducted in-vitro (laboratory) research to explore Nilox midi's activity against bacterial and fungal isolates, including strains with multidrug-resistant properties. Laboratory data report measurements of activity against these resistant strains. However, these are strictly in-vitro findings and clinical trials specifically focusing on patients with confirmed MDR infections are lacking. Furthermore, while the majority of consolidated evidence applies to adult females, data for certain groups, such as children and those with complex health issues, remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Nilox midi (FAQ)

Q: Do you need a special prescription to get Nilox midi?

Yes, official regulatory documents classify Nilox midi as a prescription anti-infective medicine. This classification means that a prescription from a qualified healthcare professional is required to obtain this medicine.

Q: Is Nilox midi a form of narcotic or controlled substance?

No. Official regulatory records in jurisdictions like the United States state that the active substance, Nitroxoline, has no DEA Schedule designation. This regulatory status indicates that the medicine is not classified as a narcotic or controlled substance.

Q: What is the mechanism of action of Nilox midi in simple terms?

The action of Nilox midi is driven by its active ingredient binding to and removing essential metal ions from the microbial environment—a process called chelation. By depriving the bacteria and fungi of these vital cofactors, the medicine effectively halts their replication and proliferation.

Q: How quickly should I expect to feel a difference after starting Nilox midi?

Pharmacological data indicates the drug is quickly absorbed after being taken orally. The active ingredient reaches high concentrations in the urinary tract, where its anti-infective action is primarily targeted, in approximately one hour.

Q: Does Nilox midi have a generic version available?

The core active ingredient, Nitroxoline, is a non-proprietary chemical compound that may be supplied by various manufacturers. The availability of a specific generic finished product will depend on the market authorization status and local regulations in a given region.

Q: How long does Nilox midi stay in your system?

Pharmacological information states that the drug is quickly absorbed, metabolized in the liver, and primarily eliminated via the kidneys, with around 60% of the drug excreted through the urine.

Q: Can Nilox midi affect my ability to drive or operate machinery?

Official safety information reports that very rare neurological side-effects, such as fatigue, vertigo, and an insecurity of gait, have been reported by some users. Official product information notes these effects are very rare, and individuals should be aware of how they respond to the medicine before engaging in activities that require full attention.

Q: Why do some people say they feel tired when they take Nilox midi?

Official regulatory information lists fatigue as a potential side effect, noting it as a very rare neurological reaction. The appearance of fatigue in patients is included in the official safety profile based on reports gathered during clinical use and ongoing surveillance.

Q: Can older adults (over 65) safely use Nilox midi?

Official eligibility rules state that older adults require special care during use of Nilox midi. This statement in the official eligibility rules indicates that use in older adults may require a specific assessment or closer follow-up due to the need for special care.

Q: Is Nilox midi suitable for teenagers?

The film-coated tablet formulation is officially not intended for children under a specified minimum age (often 4 years). While evidence is consolidated mainly from adult studies, use in pediatric groups, including adolescents, is sometimes examined in clinical settings.

Q: Can you split or crush Nilox midi tablets?

The medicine is formulated as a film-coated tablet or capsule intended for oral ingestion with water. Official regulatory guidance does not provide explicit instructions allowing the splitting or crushing of the tablet. When explicit instructions for alteration are absent, the medicine is typically intended to be ingested in its original dosage form.

Q: What should I do if the side effects of Nilox midi seem too strong?

Official regulatory guidance emphasizes that severe or unexpected reactions should be brought to the attention of a healthcare professional immediately. Official labeling also provides detailed contact information for reporting suspected adverse reactions to the relevant national health authority.

Q: What is the regulatory status of Nilox midi in the US/EU?

The active ingredient Nitroxoline has been evaluated and authorized for use by regulatory bodies across multiple governmental jurisdictions. This includes agencies in parts of the European Union (EU) and the United Kingdom, where its status determines its legal use and availability.

Q: Is there a maximum time someone can stay on Nilox midi?

The established use includes a short-term regimen for active infection and a reduced frequency for prophylaxis (prevention). Official documentation notes that available research evidence is limited concerning the long-term safety and outcomes for extended durations of use that exceed the specified regimens.

How should Nilox midi be stored and disposed of?

How to Store and Dispose of Nilox midi?

Specific, detailed storage, handling, and disposal requirements for Nilox midi are not publicly documented within the labeling information provided by major authoritative government regulatory agencies, such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). Consequently, an official regulatory storage profile cannot be confirmed from these public sources.

Since mandatory conditions like temperature range, light or moisture protection, and in-use stability periods are not available in public government databases, consult the specific product packaging or contact a healthcare provider for any necessary instructions.